Andrew has made over 7 trades of the Kala Bio stock since 2016, according to the Form 4 filled with the SEC. Most recently he sold 156,573 units of KALA stock worth 57,932$ on 4 June 2018.
The largest trade he's ever made was selling 161,906 units of Kala Bio stock on 5 June 2017 worth over 207,240$. On average, Andrew trades about 20,069 units every 34 days since 2016. As of 4 June 2018 he still owns at least 1,183,419 units of Kala Bio stock.
You can see the complete history of Mr. Koven stock trades at the bottom of the page.
Andrew Ian Koven serves as Lead Independent Director of the Company. Mr. Koven has served as a member of our board of directors since September 2017 and as our Lead Independent Director since December 2018. Mr. Koven was, until his retirement in January 2019, the President and Chief Business Officer of Aralez Pharmaceuticals Inc., or Aralez, a public specialty pharmaceutical company, and served in that role with the company’s predecessor, Pozen Inc., commencing in June 2015. Prior to joining Pozen, Mr. Koven served as Executive Vice President, Chief Administrative Officer and General Counsel of Auxilium Pharmaceuticals Inc., a public specialty biopharmaceutical company, from February 2012 until January 2015, when it was acquired by Endo International plc. Mr. Koven served as President and Chief Administrative Officer and a member of the board of directors of Neurologix, Inc., a company focused on the development of multiple innovative gene therapy development programs, from September 2011 to November 2011. Before Neurologix, Mr. Koven served as Executive Vice President and Chief Administrative and Legal Officer of Inspire Pharmaceuticals, Inc., a public specialty pharmaceutical company, from July 2010 until May 2011 when it was acquired by Merck & Co., Inc. Previously, Mr. Koven served as Executive Vice President, General Counsel and Corporate Secretary of Sepracor Inc. (now Sunovion), a public specialty pharmaceutical company, from March 2007 until February 2010 when it was acquired by Dainippon Sumitomo Pharma Co., Ltd. Prior to joining Sepracor, Mr. Koven served as Executive Vice President, General Counsel and Corporate Secretary of Kos Pharmaceuticals, Inc., a public specialty pharmaceutical company, from August 2003 until its acquisition by Abbott Laboratories (now AbbVie) in December 2006.
As the Lead Independent Director of Kala Bio, the total compensation of Andrew Koven at Kala Bio is 146,222$. There are 8 executives at Kala Bio getting paid more, with Mark Iwicki having the highest compensation of 2,556,170$.
Andrew Koven is 62, he's been the Lead Independent Director of Kala Bio since 2018. There are 2 older and 15 younger executives at Kala Bio. The oldest executive at Kala Bio Inc. is Dr. Kim Brazzell Ph.D., 68, who is the Head of R&D and Chief Medical Officer.
Andrew's mailing address filed with the SEC is C/O KALA BIO, INC., 1167 MASSACHUSETTS AVENUE, ARLINGTON, MA, 02476.
Over the last 7 years, insiders at Kala Bio have traded over 2,579,128$ worth of Kala Bio stock and bought 23,705,318 units worth 209,975,371$ . The most active insiders traders include Capital Management, L.P.Ra ...、Capital Management, L.P.Ra ...、Rajeev M. Shah. On average, Kala Bio executives and independent directors trade stock every 31 days with the average trade being worth of 2,090,132$. The most recent stock trade was executed by Todd Bazemore on 26 June 2024, trading 4,653 units of KALA stock currently worth 22,102$.
kala pharmaceuticals, inc. (kala) is a biopharmaceutical company focused on the development and commercialization of therapeutics using our proprietary nanoparticle-based mucus penetrating particles, or mpp, technology, with an initial focus on the treatment of eye diseases. for more information, please visit kala’s website at www.kalarx.com.
Kala Bio executives and other stock owners filed with the SEC include: